Core Viewpoint - Xizi Health, a company that has rapidly grown through live streaming, has submitted its IPO application to the Hong Kong Stock Exchange, achieving nearly 1.7 billion RMB in annual revenue within a few years. However, it faces significant challenges due to its heavy reliance on online traffic, a marketing-heavy approach with limited R&D, and dependence on contract manufacturing for core products [3][34]. Group 1: Business Model and Growth - Xizi Health has adopted a "traffic explosion + light asset contract manufacturing + multi-brand positioning" strategy, leveraging influencer marketing and traffic investment to quickly create popular products [4][38]. - The company has expanded its own brand matrix significantly since launching its first proprietary brand, fiboo, in 2021, followed by several others targeting different health segments [5][39]. - The four main brands cover women's nutrition, weight management, and sports health, with key products including iron gummies, meal replacement shakes, protein powders, and creatine [6][39]. Group 2: Financial Performance - Xizi Health's revenue has shown consistent growth, with projected revenues of 1.69 billion RMB in 2024, a 17% increase year-on-year, and 1.6 billion RMB in the first three quarters of 2025, reflecting a 23% growth rate [10][42]. - The company's net profit for 2023, 2024, and the first three quarters of 2025 is reported at 93.86 million RMB, 149.27 million RMB, and 118.48 million RMB respectively [11][43]. - The proportion of revenue from proprietary brands has increased significantly, from 42.4% in 2023 to 88.5% in 2024, indicating a shift towards greater business independence and profitability [10][42]. Group 3: Marketing and Sales Strategy - The company heavily relies on online channels for revenue, with online sales contributing 99.4%, 98.9%, and 98.9% of total revenue in 2023, 2024, and the first three quarters of 2025 respectively [17][19]. - Xizi Health's sales expenses have escalated, reaching 7.56 billion RMB in the first three quarters of 2025, which constitutes 47% of its revenue, highlighting the cost of maintaining its traffic-driven growth model [20][21]. Group 4: Challenges and Risks - The company faces significant risks due to its reliance on a few suppliers, with the top five suppliers accounting for 58.6%, 57.4%, and 45% of total procurement in 2023, 2024, and the first three quarters of 2025 respectively [27]. - Xizi Health's patent portfolio is weak, with only 2 out of 23 patents being invention patents, indicating a lack of core technology and substantial innovation [24][26]. - The company has received numerous complaints regarding product quality and marketing practices, which could undermine its brand reputation and customer loyalty [28].